Yamazaki H, Shimada T
Osaka Prefectural Institute of Public Health, Nakamichi, Japan.
Arch Biochem Biophys. 1997 Oct 1;346(1):161-9. doi: 10.1006/abbi.1997.0302.
Roles of human cytochrome P450 (P450 or CYP) 2C9, 2C19, and 3A4 in the oxidation of progesterone and testosterone were studied in recombinant P450 enzymes and in human liver microsomes. In vitro inhibition experiments showed that progesterone and its 17alpha- and 21-hydroxylated metabolites and 11-deoxycortisol suppressed the CYP2C19-dependent R-warfarin 7-hydroxylation activities, with progesterone being the most active. These steroid chemicals also inhibited CYP2C9-dependent S-warfarin 7-hydroxylation activities though lesser extents seen with those in CYP2C19 enzyme. Progesterone was found to be a competitive inhibitor of CYP2C19 and CYP2C9 in human liver microsomes. Recombinant CYP2C19 catalyzed progesterone to form 21-hydroxyprogesterone as a major product and 16alpha- and 17alpha-hydroxyprogesterone as minor products. CYP2C9 also had progesterone 21-hydroxylation activities, although the activities were lower than those catalyzed by CYP2C19. Vmax/Km ratios for the progesterone 21-hydroxylation activity of CYP2C19 were determined to be 13- and 32-fold higher than those of CYP2C9 and 3A4, respectively. CYP3A4 oxidized progesterone to form 16alpha-, 6beta-, and 2beta-hydroxyprogesterone as major products and 21-hydroxyprogesterone as a minor product, but did not produce detectable levels of 17alpha-hydroxyprogesterone. Immunoinhibition experiments suggested that anti-CYP2C9 (which inhibits both CYP2C9 and CYP2C19 catalytic activities) suppressed the progesterone 21-hydroxylation activities catalyzed by liver microsomes of humans and monkeys and that anti-CYP2C11 inhibited the progesterone 21-hydroxylation activities catalyzed by liver microsomes of male rats. CYP2C19 was also found to oxidize testosterone at 17-position to form androstenedione. Androstenedione formation catalyzed by liver microsomes of humans and monkeys and of male rats was suppressed by anti-CYP2C9 and anti-CYP2C11, respectively. These results suggest that CYP2C19 plays important roles in the oxidation of progesterone and testosterone in human liver microsomes, although the physiological significance of these metabolic pathways remains unclear. CYP2C9 may have some, but lesser extent than those by CYP2C19, of the catalytic roles for the metabolism of progesterone and testosterone by human liver microsomes.
在重组P450酶和人肝微粒体中研究了人细胞色素P450(P450或CYP)2C9、2C19和3A4在孕酮和睾酮氧化中的作用。体外抑制实验表明,孕酮及其17α-和21-羟基化代谢产物以及11-脱氧皮质醇抑制了CYP2C19依赖性R-华法林7-羟基化活性,其中孕酮活性最强。这些甾体化学物质也抑制CYP2C9依赖性S-华法林7-羟基化活性,但其程度低于在CYP2C19酶中的抑制程度。发现孕酮是人肝微粒体中CYP2C19和CYP2C9的竞争性抑制剂。重组CYP2C19催化孕酮形成主要产物21-羟孕酮以及次要产物16α-和17α-羟孕酮。CYP2C9也具有孕酮21-羟基化活性,尽管其活性低于CYP2C19催化的活性。CYP2C19的孕酮21-羟基化活性的Vmax/Km比值分别比CYP2C9和3A4高13倍和32倍。CYP3A4将孕酮氧化形成主要产物16α-、6β-和2β-羟孕酮以及次要产物21-羟孕酮,但未产生可检测水平的17α-羟孕酮。免疫抑制实验表明,抗CYP2C9(抑制CYP2C9和CYP2C19催化活性)抑制人和猴肝微粒体催化的孕酮21-羟基化活性,抗CYP2C11抑制雄性大鼠肝微粒体催化的孕酮21-羟基化活性。还发现CYP2C19在17位氧化睾酮形成雄烯二酮。人和猴以及雄性大鼠肝微粒体催化的雄烯二酮形成分别被抗CYP2C9和抗CYP2C11抑制。这些结果表明,CYP2C19在人肝微粒体中孕酮和睾酮的氧化中起重要作用,尽管这些代谢途径的生理意义尚不清楚。CYP2C9在人肝微粒体对孕酮和睾酮的代谢中可能具有一些催化作用,但程度低于CYP2C19。